UC San Diego School of Medicine Names New Division Chief for Gastroenterology


August 23, 2010  |  

William Sandborn, MD, has been named the Division Chief for Gastroenterology in the University of California, San Diego Department of Medicine pending UCSD campus approval of his faculty appointment.  Currently Vice Chair of the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota, Sandborn is expected to begin at UC San Diego School of Medicine at the end of the year.

William Sanborn

William Sandborn, MD

After medical school and an internal medicine residency at Loma Linda University, Sandborn completed a gastroenterology fellowship at the Mayo Clinic in 1993. In addition to serving as vice chair, he is the Dorothy A. Adair Professor of Medicine at Mayo Clinic College of Medicine and Associate Dean of Research for Intellectual Property and Industry Relations at Mayo Clinic. 

Sandborn has published more 340 peer reviewed articles, including articles in the New England Journal of Medicine, The Lancet, JAMA, The Annals of Internal Medicine, and the journal Gastroenterology. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease. He is a key thought leader in the treatment of inflammatory bowel disease and has a large clinical practice in patients with these challenging illnesses.

# #  # 

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu

Related Specialties


Media Contact

Share This Article

Related News

New technique can reveal previously undetectable bacteria in places where they aren’t wanted — such as a spacecraft assembly facility, a neonatal intensive care unit and an abalone rearing center.
Each year, at precisely the same moment — 12 p.m. on the East coast, 9 a.m. on the West — thousands of graduating medical school students across the country simultaneously tear open an envelope. The s ...
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate t ...
In clinical trial, treatment significantly reduced liver fat in NAFLD and NASH patients, offering possible new treatment for conditions that currently lack medical remedies.

Follow Us